

|                          |           |
|--------------------------|-----------|
| <b>OMB APPROVAL</b>      |           |
| OMB Number:              | 3235-0287 |
| Estimated average burden |           |
| hours per response:      | 0.5       |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |   |  |
|--|---|--|
| 1. Name and Address of Reporting Person*<br><u>WIDDER KENNETH J</u><br><br>(Last) (First) (Middle)<br><u>C/O EVOKE PHARMA, INC.</u><br><u>12555 HIGH BLUFF DRIVE, SUITE 385</u><br><br>(Street)<br><u>SAN DIEGO CA 92130</u><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>Evoke Pharma Inc [ EVOK ]</u> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner<br>Officer (give title below) Other (specify below) |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>09/30/2013</u>           |  |
| 4. If Amendment, Date of Original Filed (Month/Day/Year)   |   |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |       | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price |   |  |   |
| Common Stock                    | 09/30/2013                           |  | C                              |   | 1,054,262   | A          | (1)   | 1,054,262   | I  | Directly owned by LVP III <sup>(2)</sup>              |
| Common Stock                    | 09/30/2013                           |  | C                              |   | 52,711  | A          | (1)   | 52,711  | I  | Directly owned by Associates <sup>(2)</sup>           |
| Common Stock                    | 09/30/2013                           |  | C                              |   | 26,356  | A          | (1)   | 26,356  | I  | Directly owned by Partners <sup>(2)</sup>             |
| Common Stock                    |                                      |  |                                |   |   |            |       | 5,250   | I  | Directly owned by LVP <sup>(2)</sup>                  |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |                            | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|----------------------------|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date | Title   | Amount or Number of Shares |  |  |   |  |
| Series A Preferred Stock <sup>(1)</sup>    | (1)  | 09/30/2013                           |  | C                              |   | 5,271,317  |     | (3)  | (4)             | Common Stock  | 1,054,262                  | (1)  | 0  | I   | Directly owned by LVP III <sup>(2)</sup>               |
| Series A Preferred Stock <sup>(1)</sup>    | (1)  | 09/30/2013                           |  | C                              |   | 263,556  |     | (3)  | (4)             | Common Stock  | 52,711                     | (1)  | 0  | I   | Directly owned by Associates <sup>(2)</sup>            |
| Series A Preferred Stock <sup>(1)</sup>    | (1)  | 09/30/2013                           |  | C                              |   | 131,784  |     | (3)  | (4)             | Common Stock  | 26,356                     | (1)  | 0  | I   | Directly owned by Partners <sup>(2)</sup>              |

**Explanation of Responses:**

- The outstanding shares of Series A Preferred Stock automatically converted on a five-to-one basis into shares of Common Stock rounded down to the next whole number for no additional consideration immediately prior to the consummation of the Issuer's initial public offering.
- The reported securities are owned directly by each of LVP<sup>(2)</sup>, LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- The securities are immediately convertible.
- The securities have no expiration date.

**Remarks:**

/s/ Matthew J. D'Onofrio,  
Attorney-in-fact for Kenneth J. Widder 10/02/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.